Grifols SA (G0FB) Q2 2026 Earnings Report

Overall the call conveys a constructive and confident tone: the company reported modest top-line growth with strong momentum in Biopharma—notably IG and subcutaneous IG—improving adjusted EBITDA, higher group profit, and better free cash flow. Strategic initiatives (Egypt plasma ramp, diagnostics platform development, Biopharma reorganization, Biotest turnaround) and debt refinancing strengthen the long‑term profile. Near-term headwinds include albumin pricing effects in China, one‑off costs from donor center closures, and transitional diagnostics comparability, but management provided clear mitigation plans and timing for expected benefits.

The company reiterated full‑year 2026 guidance while highlighting a strong H1: group revenues of €3.574bn (up 2.6% cc) with Q2 revenues €1.874bn; Biopharma +5.4% cc (IG +12.8% cc) and XEMBIFY accelerating with strong double‑digit growth; adjusted EBITDA of €472m in Q2 (25.2% margin) and €854m in H1 (≈23.9% margin); reported gross margin 37.6% in Q2 / 37.1% H1 (excluding one‑offs 39.4% Q2 / 38.6% H1); H1 group profit $227m (+28.7% YoY) and free cash flow before M&A €91m (+€103m YoY) with full‑year FCF guidance €500–575m; one‑offs include €40m (≈€25m non‑cash) for closing 29 U.S. donation centers; balance sheet: total net leverage ~4.2x, net secured 2.7x, liquidity ~$2bn; albumin expected to stabilize with H2 absolute levels in line with H2 last year; Egypt/ex‑U.S. plasma to ramp (≈25% of ex‑U.S. today, targeting ~50% by 2029 and ~1m collections in 2026 → ~3m by 2029); capital spend normalizing and cash interest expected broadly in line with 2025.